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Background: Cancer-associated fibroblasts (CAFs), which reside around tumor cells, are suggested to play a pivotal
role in tumor progression. Here we performed microarray analyses to compare gene expression profiles between CAFs
and non-cancerous gastric fibroblasts (NGFs) from a patient with gastric cancer and found that fibroblast growth factor
9 (FGF9) was a novel growth factor overexpressed in CAFs. We then examined the biological effects of FGF9 during
progression of gastric cancer.
Methods: Expression of FGF9 in CAFs and NGFs, and their secreted products, were examined by Western blotting.
The effects of FGF9 on AGS and MKN28 gastric cancer cells in terms of proliferation, invasion and anti-apoptosis were
assessed by WST-1 assay, invasion chamber assay and FACS, respectively. Furthermore, the intracellular signaling by
which FGF9 exerts its biological roles was examined in vitro.
Results: FGF9 was strongly expressed in CAFs in comparison with NGFs, being compatible with microarray data
indicating that FGF9 was a novel growth factor overexpressed in CAFs. Treatment with FGF9 promoted invasion and
anti-apoptosis through activation of the ERK and Akt signaling pathways in AGS and MKN28 cells, whereas these effects
were attenuated by treatment with anti-FGF9 neutralizing antibody. In addition, FGF9 treatment significantly enhanced
the expression of matrix metalloproteinase 7 (MMP7) in both cell lines.
Conclusions: FGF9 is a possible mediator secreted by CAFs that promotes the anti-apoptosis and invasive capability of
gastric cancer cells.
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The formation of cancerous lesions is intimately associ-
ated with their unique microenvironment. Progression is
closely correlated with the capability of cancer cells to re-
cruit and activate the surrounding stromal cells, and sub-
sequently exploit them [1]. Cancer-surrounding stromal
cells, such as fibroblasts, endothelial cells, and immune
cells, can orchestrate tumorigenesis and metastasis
through cell-to-cell interaction and/or production of sol-
uble growth factors/cytokines/chemokines [1-3]. In this* Correspondence: hfukui@hyo-med.ac.jp
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cancer-associated fibroblasts (CAFs) and have received
much attention with regard to their role in tumor progres-
sion [4,5]. Although CAFs are known to be largely differ-
ent from normal fibroblasts in non-neoplastic tissues in
terms of their gene profile, the mechanism by which CAFs
promote tumor progression is unclear. Therefore, we
compared the gene expression profiles of CAFs, focusing
especially on growth factors/cytokines/chemokines, with
those of non-cancerous gastric fibroblasts (NGFs) using
microarray assay, and subsequently isolated fibroblast
growth factor 9 (FGF9) as a novel gene that was overex-
pressed in CAFs in gastric cancer.
FGF9, a secretory protein of the FGF family, is report-
edly expressed in stromal cells including fibroblasts [6-8].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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(FGFRs) to regulate a variety of cell biological behavior, in-
cluding proliferation, differentiation, survival and motility
[9], and expression of FGF9, FGFR2c, FGFR3b and
FGFR3c has been detected in gastric and colon cancers
[10]. Thus, like other FGF family proteins, FGF9 may
play a pivotal role in the interaction between cancer
cells and their surrounding stromal cells, and it is note-
worthy that FGF9 is strongly expressed in CAFs in gas-
tric cancer. In the present study, we screened for
differences in gene expression between CAFs and NGFs
from a patient with gastric cancer. We examined the ef-
fect of FGF9 on proliferation, invasion and anti-
apoptosis of gastric cancer cells, and moreover clarified
the intracellular signaling by which FGF9 exerts its bio-
logical effects on gastric cancer cells.
Methods
Reagents and cell culture
Human recombinant FGF9 and anti-human FGF9 neu-
tralizing antibody were purchased from R&D Systems
(Minneapolis, MN, USA). Anti-extracellular signal-regulated
protein kinase (ERK), anti-phospho-specific ERK (p-ERK),
anti-Akt, anti-phospho-specific Akt (p-Akt; Ser473), and
anti-β-actin antibodies were purchased from Cell Signaling
Technology (Beverly, MA, USA).
The gastric cancer cell lines AGS was cultured in
Ham’s F-12 medium (Sigma, Aurora, Ohio, USA) with
10% fetal bovine serum (FBS; Biowest, Nuaillé, France)
in a humidified incubator at 37°C with an atmosphere of
5% CO2. Similarly, MKN28 was cultured in RPMI 1640
medium with 10% fetal bovine serum, and other five gas-
tric cancer cell lines MKN1, MKN 45, MKN74, GCIY, and
KATOIII were maintained as previously described [11].
Isolation and culture of human gastric fibroblasts
Human gastric cancer (poorly-differentiated adenocar-
cinoma) specimens were obtained from a patient who
underwent gastrectomy at Hyogo College of Medicine
Hospital in 2012. Cancer-associated fibroblasts (CAFs)
were prepared from the cancerous portion in the stomach.
Non-cancerous gastric fibroblasts (NGFs) were prepared
from non-cancerous portion with atrophic gastritis at least
50 mm far from tumor in the stomach. The tissue speci-
mens were trimmed of fat and necrotic tissue, minced
with scalpels and washed in PBS containing antibiotic-
antimycotic reagent (Anti-Anti®, GIBCO). The tissue
pieces were transferred to a 12-well microplate (IWAKI,
Tokyo, Japan) at one fragment/well. The cells were cul-
tured in DMEM medium (GIBCO, Grand Island, NY,
USA) with 10% heat-inactivated FBS at 37°C in an atmos-
phere of 5% CO2. The fibroblasts that initially grew in
a monolayer were collected, transferred to another dish
and used for experiments within the 10th passage. Thesestudies were done with the approval of the Review Board
of Hyogo College of Medicine, and informed consent was
obtained from the patient.
Microarray analysis
Using Trizol reagent (Invitrogen, Carlsbad, CA, USA),
total RNA was extracted from three sets of CAFs and
NGFs cultured. cDNA labeling, hybridizations, scanning
and data analysis were performed by Hokkaido System
Science Co., Ltd (Sapporo, Japan). Briefly, cyanine-3
(Cy3)-labeled cRNA was prepared from total RNA (0.05
μg) using a Low Input Quick Amp Labeling Kit (Agilent)
in accordance with the manufacturer’s instructions,
followed by RNAeasy column purification (QIAGEN,
Valencia, CA). Dye incorporation and cRNA yield were
checked with a NanoDrop ND-1000 Spectrophotometer.
Cy3-labeled cRNA (0.60 μg) was fragmented at 60°C for
30 min in a reaction volume of 25 μl containing 1x Agilent
fragmentation buffer and 2x Agilent blocking agent in ac-
cordance with the manufacturer’s instructions. On com-
pletion of the fragmentation reaction, 25 μl of 2x Agilent
hybridization buffer was added to the fragmentation mix-
ture and hybridized to Agilent SurePrint G3 Human Gene
Expression Microarray (8x60K ver.2.0) for 17 h at 65°C in
a rotating Agilent hybridization oven. After hybridization,
the microarrays were washed for 1 min at room
temperature with GE Wash Buffer 1 (Agilent) and for 1
min at 37°C with GE Wash buffer 2 (Agilent), then dried
immediately by brief centrifugation. Slides were scanned
immediately after washing on an Agilent DNA Microarray
Scanner (G2565CA) using one color scan setting for
8x60K array slides (Scan Area 61×21.6 mm, Scan reso-
lution 3μm, Dye channel for Green PMT set to 100%).
The scanned images were analyzed and normalized with
Feature Extraction Software 10.7.3.1 (Agilent).
RNA extraction and reverse transcription-polymerase
chain reaction (RT-PCR)
Total RNA was extracted from gastric cancer cell lines using
Trizol reagent (Invitrogen). Four microgram of total RNA
was reverse-transcribed by using oligo dT (Applied Biosys-
tems, Branchburg, NJ, USA) and 200 U of Superscript™ II
reverse transcriptase (Invitrogen) in a total volume of 20μl.
For the following PCR, pairs of oligonucleotide primers
for human FGFRs were prepared as previously described
[12]. Human FGFR2c: 5′-TGGTCGGAGGAGACGTAGA
G-3′ (Forward) and 5′-AAAGTTACATTCCGAATATAGA
GAACC-3′ (Reverse); human FGFR3b: 5′-GGAGTTCCA
CTGCAAGGTGT-3′ (Forward) and 5′ -GTGAACGCTCA
GCCAAAAG-3′ (Reverse); human FGFR3c: 5′-GGAGTTC
CACTGCAAGGTGT-3′ (Forward) and 5′-AAGCGGGAG
ATCTTGTGC-3′ (Reverse); human GAPDH: 5′-GGCTGC
TTTTAACTCTGGTA-3′ (Forward) and 5′-ATGCCAGT
GAGCTTCCCGT-3′ (Reverse). One microliter of RT
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volume containing 20 pmol of the above sets of primers,
1.25 U of Ampli-Taq DNA polymerase (Applied Biosystems,
Foster City, Calif., USA), and the final PCR buffer: 20 mM
Tris–HCl (pH 8.4), 50 mM KCl, 2.5 mM MgCl2, 10 mM
dithiothreitol, and 1 mM dNTP. The PCR amplification
was performed as follows: for FGFRs, at 95°C for 5 min
once; 40 cycles at 95°C for 30 s, at 57°C for 30 s, and at
72°C for 1 min; then at 72°C for 7 min; for GAPDH, at
95°C for 7 min once; 40 cycles at 95°C for 30 s, at 55°C
for 1 min, and at 72°C for 30 sec; then at 72°C for 7 min.Figure 1 Expression of FGF9 and its receptors in CAFs and gastric cancer
cells. (A) Morphology of gastric CAFs and NGFs. (B) Production of FGF9 in
gastric CAFs, NGFs and their conditioned medium (CM). (C) Expression of
FGF9 in CAFs of the gastric cancer lesion. Arrows indicating CAFs.
(D) Expression of FGF receptors responsible for FGF9 in gastric
cancer cell lines.Real-time RT-PCR
Real-time RT-PCR was performed using 7900H Fast
Real-Time PCR System (Applied Biosystem) as previ-
ously described [13]. The following sets of primers for
human matrix metalloproteinase 2 (MMP2), MMP3,
MMP7, MMP9, and GAPDH were prepared (Additional
file 1: Table S1). Real-time RT-PCR assays were carried
out with 200 ng RNA equivalent cDNA, SYBR Green
Master Mix (Applied Biosystems), and 500 nmol/l gene
specific primers. The PCR cycling conditions were 50°C
for 15 s, and 60°C for 60 s. The intensity of the fluores-
cent dye was determined, and each of mRNA expression
levels was normalized to GAPDH mRNA expression
levels.
Cell proliferation assay
AGS (4 × 103) and MKN28 cells (1 × 104) were seeded in
complete medium in 96-well microplates. The medium
was then replaced with one containing recombinant
FGF9 (0—10 ng/ml). WST-1 solution was added after 72
h incubation, and the plates were incubated at 37°C for
1 h. The plates were analyzed using an ELISA plate
reader at 450 nm with the reference wavelength set at
600 nm.
Cell invasion assay
Cell invasion assay was performed using BioCoat Matrigel
invasion chambers (BD Biosciences, Bedford, MA, USA)
according to the manufacturer’s protocol. Briefly, AGS
cells (1 × 105) or MKN28 cells (3 × 105) were seeded in
the insert of the Matrigel-coated invasion chamber (24
wells, 8-μm pore size) filled with serum-free medium con-
taining different concentrations of FGF9 (0–10 ng/ml).
Then, the cells were incubated with medium containing
10% FBS in the lower chamber at 37°C in 5% CO2. To in-
hibit the effects of FGF9, anti-FGF9 antibody (1 μg/ml)
was also added to the upper chamber. After incubation for
27 h, non-invading cells were removed using a cotton
swab and the cells that had invaded into the lower surface
of the membrane were fixed with ethanol. The invading
cells were then stained with hematoxylin and countedusing a microscope in five different visual fields (magnifi-
cation, x200).
Apoptosis assay
AGS (2 × 105) and MKN28 (2.5 × 105) cells were seeded
in six-well plates in routine medium for 24 h. The cells
were then deprived of serum and treated with or without
recombinant FGF9 (1–10 ng/ml) for 48h. To inhibit the
effects of FGF9, anti-FGF9 antibody (1 μg/ml) was also
added to the culture medium. After treatment, both float-
ing and attached cells were harvested, washed with PBS
and stained with AnnexinV-FITC and propidium iodide
(PI) using a MEBCYTO Apoptosis Kit (MBL, Nagoya,
Japan). Stained cells were analyzed on a FACScalibur flow
cytometer (Becton Dickinson, Franklin Lakes, NJ, USA),
and the data obtained were analyzed using CELLQUEST
software (Becton Dickinson, Mountain View, CA, USA).
Western blot analysis
Western blot analyses were performed as described previ-
ously [14]. Briefly, after treatment with or without reagent,
cells were lysed in protein extraction buffer, and protein
extract (30 μg) was fractioned by sodium dodecyl sulfate
polyacrylamide gel electrophoresis and transferred to a
nitrocellulose blotting membrane. The membrane was
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peroxidase-conjugated secondary antibody. Proteins were
detected using an enhanced chemiluminescence system
(Amersham Biosciences, Buckinghamshire, UK).
Immunohistochemistry
A total of 20 gastric cancers tissues were obtained from
specimens resected surgically at Hyogo College of Medicine.
The tissue specimen were fixed in 10% formalin solution
and embedded in paraffin. This study was approved by the
Review Board of Hyogo College of Medicine, and in-
formed consent was obtained from all patients. The char-
acteristics of gastric cancer patients were showed in
Additional file 2: Table S2.
Immunohistochemical staining for FGF9 was performed
with an LSAB+ kit using anti-FGF9 antibody (1:40; R&D
Systems, Minneapolis, MN, USA) as described previously
[15]. Finally, the sections were incubated in 3,3′-diamino-
benzide tetrahydrochloride with 0.05% H2O2 for 3 min,
and then counterstained with Mayer’s haematoxylin. To
evaluate the immunoreactivity of FGF9, at least fiveTable 1 Representative genes differentially expressed in CAF
Accession No. Symbol Gene name
Up-regulated
NM_014333 CADM1 Cell adhesion mo
CB178477 XLOC_l2_007424 gb|is39c09.y1 HR
IMAGE:6554705 5
NM_001113207 TSTD1 Thiosulfate sulfur
containing 1, tran
NM_000867 HTR2B 5-hydroxytryptam
NM_001008539 SLC7A2 Solute carrier fam
y + system), mem
NM_002010 FGF9 Fibroblast growth
NM_005559 LAMA1 Laminin, alpha 1




NM_001141919 XG Xg blood group
NM_175569 XG Xg blood group
NM_000609 CXCL12 Chemokine (C-X-
NM_014817 TRIL TLR4 interactor w
NM_002839 PTPRD Protein tyrosine p
NR_021485 EGFEM1P EGF-like and EMI
NM_198285 WDR86 WD repeat doma
NM_001164000 MECOM MDS1 and EVI1 c
NM_004335 BST2 Bone marrow str
ENST00000484765 XLOC_002912 Hypothetical LOC
Fold change values were evaluated as a ratio of normalized CAFs/normalized NGFs.different visual fields were observed at the invasive front
of gastric cancer lesions. A specimen was considered posi-
tive when FGF9-positive fibroblastic nests were observed
in the visual fields examined.Statistics analysis
All values were expressed as the mean ± SD. The data
were analyzed using unpaired two-tailed t-test. P values
of less than 0.05 were considered to indicate statistical
significance.Results
Microarray analyses of CAFs in gastric cancer tissues
We isolated CAFs and NGFs (Figure 1A) and compared
the gene expression profile of CAFs with that of NGFs
using microarray assay. Ten representative genes that
were upregulated in CAFs are listed in Table 1. Among
these genes, we targeted FGF9 as the most highly
expressed gene to examine the role of this CAF-
produced growth factor on gastric cancer cells, and ins from NGFs
Fold
change
lecule 1, transcript variant 1 273.6






ine (serotonin) receptor 2B 171.5
ily 7 (cationic amino acid transporter,
ber 2, transcript variant 2
142.5
factor 9 (glia-activating factor) 141.1
119.0
oprotein 1, transcript variant 1 116.1
112.6
ated membrane protein 3 111.3
(XG), transcript variant 2, 0.0035
(XG), transcript variant 1 0.0044
C motif) ligand 12 (CXCL12), transcript variant 2 0.0071
ith leucine-rich repeats 0.0099
hosphatase, receptor type D, transcript variant 1 0.0138
domain containing 1, pseudogene, non-coding RNA 0.0141
in 86 0.0145
omplex locus (MECOM), transcript variant 6 0.0166
omal cell antigen 2 0.0168
100507661 (LOC100507661), miscRNA 0.0172
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CAF cells produced much larger amount of FGF9 pro-
tein than NGF cells (Figure 1B). Moreover, we confirmed
that FGF9 is strongly expressed in the fibroblasts in the
stroma of the gastric cancer lesion from which CAF was
isolated (Figure 1C).
Expression of FGFR2c and FGFR3b/c in gastric cancer cell
lines
FGF9 has been reported to show high affinity for the
FGFR2c isoform and FGFR3b/c isoforms [12]. There-
fore, we examined the expression of these FGFRs in
various gastric cancer lines using RT-PCR. As shown in
Figure 1D, expression of FGFR2c was detected in all
seven gastric cancer cell lines, whereas expression ofFigure 2 Effect of FGF9 treatment on intracellular signaling in gastric cancer
with FGF9. AGS (4 × 105) and MKN28 (4 × 105) were cultured in six-well plates
protein was analyzed by Western blotting, as described in Materials and Meth
cancer cells treated with FGF9. AGS and MKN28 cells were similarly treated
neutralizing antibody on FGF9-induced Akt and ERK phosphorylation in gastric
(Ab; 1 μg/ml) for 45 min and then stimulated with FGF9 (10 ng/ml) for 30 min.FGFR3b/c was detected in six of the seven, with the ex-
ception of MKN74. These findings suggested that gas-
tric cancer cells have the capacity to respond to FGF9
stimulation.FGF9 activates the ERK and AKT signaling pathways in
gastric cancer cells
We investigated the effect of FGF9 stimulation on pos-
sible pathways including ERK and Akt in gastric cancer
cell lines [16]. Expression of both p-Akt and p-ERK was
dose-dependently enhanced by FGF9 stimulation in AGS
and MKN28 cells (Figure 2A). The enhancement was
evident from 15 min after FGF9 (10 ng/mL) treatment
in both cell lines (Figure 2B). Moreover, we examinedcells. (A) Phosphorylation of Akt and ERK in gastric cancer cells treated
and treated with various concentrations of FGF9 for 30 min. Extracted
ods. (B) Time course change in Akt and ERK phosphorylation in gastric
with FGF9 (10 ng/ml) for the indicated times. (C) Effect of anti-FGF9
cancer cells. AGS and MKN28 cells were pretreated with anti-FGF9 antibody
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cancer cells and found that the increased expression of
p-Akt and p-ERK elicited by FGF9 stimulation was at-
tenuated by concomitant administration of anti-FGF9
neutralizing antibody (Figure 2C).Effect of FGF9 on cell proliferation, invasion and
anti-apoptosis in gastric cancer cells
Since FGF9 is known to have a mitogenic effect on some
cell types [17], we first tested the effect of FGF9 on the
growth kinetics of gastric cancer cells. However, we
found no effect of FGF9 on cell proliferation in the AGS
and MKN28 cell lines (Figure 3A).
To further identify the possible role of FGF9 in tumor
progression, we examined whether exogenous FGF9 con-
fers an anti-apoptotic effect on gastric cancer cells. FACS
analyses revealed that the number of annexin V-positive
AGS cells was significantly smaller in the FGF9-treatedFigure 3 Effect of FGF9 on growth and anti-apoptosis of gastric cancer ce
FGF9 on anti-apoptosis capability of gastric cancer cells. (B) Representative
treated with FGF9 (10 ng/ml) and evaluated as described in Materials and Me
treated with FGF9. (D) Effect of anti-FGF9 neutralizing antibody (Neu Ab; 1 μg
All the results are expressed as the mean ± SD of four samples. Significant
the FGF9-treated group: #P <0.05, ##P <0.01.group than in the control group, and similar findings
were obtained in MKN28 cells (Figure 3B and C). Fur-
thermore, this effect of FGF9 was abolished by con-
comitant administration of anti-FGF9 neutralizing
antibody in both cell lines (Figure 3D).
Moreover, we next examined the effect of FGF9 on the
invasive ability of gastric cancer cells. When AGS cells
were stimulated with FGF9 (1–10 ng/mL), the number
of invasive cells was significantly increased (Figure 4A).
Similarly, the invasive ability of MKN28 cells was signifi-
cantly enhanced dose-dependently by FGF9 stimulation
(Figures 4A). We then examined whether this pro-invasive
effect of FGF9 could be abolished by adding a neutralizing
antibody. In both cell lines, after concomitant administra-
tion of FGF9 neutralizing antibody (1 μg/ml), the number
of invasive cells was significantly decreased in comparison
with cells treated with FGF9 alone (10 ng/mL) (Figure 4B).
In addition, we examined whether FGF9 induced the ex-
pression of MMPs, which play a pivotal role in invasion oflls. (A) Effect of FGF9 on growth of gastric cancer cells. (B-D) Effect of
graphs of FACS analysis using Annexin V-FITC staining. AGS cells were
thods. (C) Changes in the number of apoptotic AGS and MKN28 cells
/ml) on FGF9 (10 ng/ml)-induced anti-apoptosis in AGS and MKN28 cells.
ly lower than control: *P <0.05, **P <0.01. Significantly greater than
Figure 4 Effect of FGF9 on invasion and MMPs expression of gastric cancer cells. (A) Effect of FGF9 on gastric cancer cell invasion. Change in
number of invasive AGS and MKN28 cells treated with FGF9 were examined. Photographs showing representative images of invasive gastric
cancer cells in the control and FGF9-treated groups. (B) Effect of anti-FGF9 neutralizing antibody (Neu Ab; 1 μg/ml) on FGF9 (10 ng/ml)-induced
invasion of AGS and MKN28 cells. (C) Effect of FGF9 on expression of MMPs in gastric cancer cells. All the results are expressed as the mean ± SD
of four samples. Significantly greater than control: *P <0.05, **P <0.01. Significantly lower than the FGF9-treated group: #P <0.05, ##P <0.01.
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commonly enhanced the expression of MMP7 in both
AGS and MKN28 cells.
Clinicopathological significance of FGF9 expression in
gastric cancer-associated fibroblasts
Of the 20 gastric cancer tissue samples examined, sixteen
(80%) was positive for FGF9 expression. Regarding the
clinicopathological features, none of the parameters ─
age, gender, tumor location, histological type, or tumor
stage ─ had a significant relationship to FGF9 expression
(Additional file 2: Table S2).
Discussion
It is believed that tumor development and progression
depend on cross-talk between cancer cells and their sur-
rounding stromal cells. As a major stromal population,“activated” fibroblasts, referred to as CAFs, have been
suggested to promote tumorigenesis using various mo-
lecular signals, and in the present study we isolated
FGF9 as a novel gene that was overexpressed in CAFs in
gastric cancer. Accumulating evidence, including our
present data, have shown that CAFs differ from NGFs in
terms of not only morphology but also gene expression
profiles [18,19], although the underlying mechanisms re-
sponsible for these differences are still unclear. On the
basis of recent evidence, it is tempting to propose that
tumor cells initiate a switch from NGFs to CAFs
through some form of signaling [20] or that CAFs ori-
ginate from cancer cells through epithelial-mesenchymal
transition [21,22]. Interestingly, it is widely accepted that
the FGF family is crucial for epithelial-mesenchymal
transition, not only during development but also in car-
cinogenesis [9,23]. In the present study, we showed that
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more gastric cancer cells have receptors that are respon-
sive to FGF9, suggesting that FGF9 may be a potential
mediator between CAFs and gastric cancer cells.
What is the possible role of FGF9 in the pathogenesis
of gastric cancer? Since FGF9 serves as mitogen for
prostate or ovarian cancer [17,24], we first investigated
the proliferation of gastric cancer cells in the presence of
FGF9 in vitro. Subsequently, FGF9 failed to promote the
proliferation of both AGS and MKN28 gastric cancer
cell lines; however, we cannot exclude the possibility that
FGF9 may serve as mitogen for other types of gastric
cancer cells because FGF9 promotes the proliferation of
other gastric cancer cells such as AZ521 or SGC-7901
[25,26]. On the other hand, we clarified in the present
study that FGF9 has an anti-apoptotic effect on gastric
cancer cells, in accord with the findings of several previ-
ous studies [26,27]. In support of this finding, Akt and
ERK pathway signaling, crucial for anti-apoptosis, was
commonly activated in both gastric cancer cell lines.
Furthermore, FGF9-induced Akt and/or ERK phosphor-
ylation and the resulting cell invasion was abolished by
blocking FGF9 stimulation, suggesting that FGF9 at least
acts as an anti-apoptotic factor.
We also examined whether FGF9 promotes the inva-
sive ability of gastric cancer cells. In vitro studies dem-
onstrated that FGF9 treatment increased the number of
invading gastric cancer cells, whereas this increased in-
vasive ability was suppressed by adding FGF9 neutraliz-
ing antibody. Although it is unclear how FGF9 promotes
the invasion of gastric cancer cells, degradation of the
extracellular matrix is an important part of this process
[28]. In this context, it is accepted that MMPs play a
central role in such cell behavior and promote the inva-
sive capacity of various malignancies [29]. Therefore, we
screened for MMPs that are linked to FGF9 stimulation
and found that MMP7 was potentially involved. Interest-
ingly, recent studies have emphasized the importance of
MMP7 in gastric cancer progression, since MMP7 has
potential to not only degrade the extracellular matrix
but also confer an anti-apoptotic effect on cancer cells
[30-32]. Accordingly, in a future study, we intend to
focus on the FGF/MMP7 axis in the context of gastric
cancer cell invasion.
Conclusion
In summary, we have shown that gastric CAFs differ
from their corresponding NGFs in terms of their gene
expression profiles, and propose that FGF9 is a potential
molecule that mediates cross-talk between CAFs and
gastric cancer cells. Moreover, we have clarified that
FGF promotes the anti-apoptosis and invasive capability
of gastric cancer cells. Taken together, our data suggest
that FGF9 is a possible mediator secreted from cancer-associated fibroblasts that promotes the anti-apoptosis
and invasive capability of gastric cancer cells.
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